

REVIEW ARTICLE

Gut dysbiosis in Parkinson's disease: A systematic review of human studies

Arberesha Bexheti-Ferati^{1†}, Kenan Ferati^{1†}, Alessio Danilo Inchingolo^{2†}, Grazia Marinelli², Paola Bassi², Rosalba Lagioia², Antonio Rizzo², Francesco Inchingolo², Francesca Vinjoli³, Andrea Palermo⁴, Ioana Roxana Bordea^{5*}, Cinzia Maspero^{6,7}, Giuseppe Minervini^{8*}, Angelo Michele Inchingolo^{2,6} and Gianna Dipalma^{2,6}

¹Faculty of Medicine, University of Tetovo, Tetovo, Polog Region, North Macedonia

²Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Puglia Region, Italy

³Department of Medical Sciences, Catholic University "Our Lady of Good Counsel", Tirana, Albania

⁴Department of Experimental Medicine, University of Salento, Lecce, Italy

⁵Department of Oral Rehabilitation, Faculty of Dentistry, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Transylvania, Romania

⁶Department of Biomedical, Surgical and Dental Sciences, Milan University, Milan, Italy

⁷Cà Granda Scientific Institute for Research, Hospitalization, and Healthcare, Major Policlinic Hospital, Milan, Italy

⁸Multidisciplinary Department of Medical-Surgical and Odontostomatological Specialties, University of Campania "Luigi Vanvitelli", Naples, Italy

[†]These authors contributed equally to this work.

*Corresponding authors:

Ioana Roxana Bordea

(roxana.bordea@ymail.com);

Giuseppe Minervini

(giuseppe.minervini@unicampania.it)

Citation: Bexheti-Ferati A, Ferati K, Inchingolo AD, *et al.* Gut dysbiosis in Parkinson's disease: A systematic review of human studies. *Eurasian J Med Oncol.* 2026;10(2):025510527. doi: 10.36922/EJMO025510527

Received: December 17, 2025

Revised: January 21, 2026

Accepted: January 31, 2026

Published online: April 23, 2026

Copyright: © 2026 Author(s).

This is an Open-Access article distributed under the terms of the Creative Commons Attribution License, permitting distribution, and reproduction in any medium, provided the original work is properly cited.

Publisher's Note: AccScience Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Introduction: Parkinson's disease (PD) is increasingly correlated to gastrointestinal disturbances and intestinal microbiota alterations. Growing evidence suggests that shifts in gut microbial communities may influence immune activation and metabolic pathways relevant to PD.

Objective: This systematic review examines microbial changes in PD and their clinical relevance.

Methods: A systematic search of PubMed, Scopus, and Web of Science identified 819 records. After removing duplicates and screening, 521 full-text articles were evaluated. Ten studies met the inclusion criteria, focusing on human subjects and original data on gut microbiota composition, function, or modulation in PD.

Results: The microbiome profile most frequently reported in PD includes a drop in overall diversity and in bacterial taxa associated with short-chain fatty acid production, alongside a shift toward taxa commonly associated with inflammatory states (e.g., Enterobacteriaceae). Most studies reported associations between dysbiosis and motor severity, constipation, autonomic dysfunction, and neuropsychiatric symptoms. Interventions such as resistant starch supplementation and acupuncture improved microbial profiles and some clinical outcomes. Machine-learning approaches showed promising diagnostic potential based on microbial signatures.

Conclusions: Gut dysbiosis is significantly associated with PD clinical features. Although early evidence suggests potential therapeutic and diagnostic applications, methodological heterogeneity and small sample sizes highlight the need for standardized, longitudinal research.

Keywords: Parkinson's disease; Gut microbiota; Gut–brain axis; Neuroinflammation; α -synuclein; Probiotics; Fecal microbiota transplantation

1. Introduction

Parkinson's disease (PD) is a steadily progressive neurodegenerative condition classically linked to the loss of dopaminergic neurons in the substantia nigra pars compacta, which underlies core motor features including bradykinesia, resting tremor, rigidity, and postural instability. In recent decades, however, PD has been reframed as a multisystem disease with manifestations extending well beyond the motor domain.^{1–4} Non-motor symptoms, including constipation, hyposmia, sleep disturbances, depression, anxiety, autonomic dysfunction, and cognitive impairment, are now considered integral components of the disease, often appearing years before motor deficits become clinically evident. This long prodromal phase has stimulated increasing interest in peripheral mechanisms that might contribute to the initiation and progression of PD.

Among peripheral systems, the gastrointestinal tract has become a focal point for research. Gastrointestinal symptoms are highly prevalent in PD, with chronic constipation representing one of the earliest and most persistent complaints.^{5,6} Neuropathological evidence has identified α -synuclein deposits within the enteric nervous system, including in subjects without a clinical PD diagnosis, which aligns with the idea that disease-associated changes may begin in the gastrointestinal tract. This model is further supported by the proposed spread of misfolded α -synuclein from the gut to the central nervous system through vagal pathways, offering a rationale for the early gastrointestinal features frequently observed in PD.^{7–11}

Parallel to these insights, scientific interest has increasingly shifted toward the gut microbiota, a complex microbial ecosystem essential for digestion, metabolic homeostasis, immune regulation, and the maintenance of the intestinal barrier. In recent years, the concept of gut dysbiosis, a disruption in the normal composition or function of the gut microbiota, has emerged as a key factor in the pathogenesis of systemic and neurological diseases.^{12–21} Alterations in microbial populations have been shown to influence systemic inflammation, oxidative stress, production of neuroactive metabolites, and permeability of the gut barrier, all processes that may play a role in PD pathophysiology. Research conducted across different populations consistently reports specific microbial signatures in individuals with PD, including reduced levels

of short-chain fatty acid (SCFA)-producing bacteria and increased abundance of pro-inflammatory taxa.

These abnormalities have been linked to both gastrointestinal and neurological manifestations, suggesting that gut dysbiosis may contribute to the disease through multiple interconnected pathways.^{22–26} Growing interest in the gut–brain axis, a bidirectional communication network connecting the central nervous system and the gastrointestinal tract, has provided a biological basis for these interactions. Microbial metabolites can influence neuronal activity, immune signaling, and barrier integrity, offering plausible mechanisms through which gut dysbiosis may modulate neurodegenerative processes. As a result, microbiota-directed therapeutic approaches, including dietary modification, probiotic and prebiotic supplementation, and fecal microbiota transfer, have gained attention, although the current evidence remains preliminary and heterogeneous.^{27,28}

Given the rapid expansion of research in this area, a systematic synthesis of the available studies is essential to clarify the nature of microbial alterations in PD, their clinical relevance, and their potential mechanistic implications.^{29–33}

1.1. The gut microbiota and its role in human health

The intestinal microbiome is a remarkably complex and highly adaptable ecosystem composed of trillions of microbes residing in the human gastrointestinal system.^{34–38} This ecosystem includes bacteria, archaea, viruses, and fungi that coexist in a finely regulated equilibrium essential for maintaining host health. Microbiota composition is highly individualized and influenced by several determinants, including host genetics, early-life microbial exposure, diet, physical activity, environmental factors, and medication use, such as antibiotics or proton pump inhibitors.^{39–48} Despite this variability, several core functions of the microbiota remain consistent across individuals and are fundamental in sustaining physiological balance.^{49–53} Among its primary functions, the gut microbiota contributes to the digestion and fermentation of otherwise indigestible dietary components, leading to the production of SCFA, such as acetate, propionate, and butyrate, which fuel colon epithelial cells and provide anti-inflammatory, as well as immunoregulatory actions throughout the body.^{54–58} In addition to nutrient processing, the gut microbiota plays a crucial role in immune development

and tuning, shaping immune-cell responses, modulating cytokine responses, and helping maintain tolerance toward commensal microorganisms, thereby preventing inappropriate inflammatory reactions.⁵⁹⁻⁶³ Another fundamental role of the microbiota is its contribution to intestinal barrier function. By modulating tight-junction proteins, mucus production, and epithelial turnover, a well-regulated microbial community helps preserve the permeability of the gastrointestinal barrier.⁶⁴⁻⁶⁸

Disruption of these mechanisms, often caused by dysbiosis, may increase gut permeability, a condition known as “leaky gut,” which, in turn, allows the translocation of microbial products, such as lipopolysaccharides, into the bloodstream, triggering low-grade inflammation.⁶⁹⁻⁷³

Beyond the gastrointestinal tract, microbial metabolites and signaling molecules reach distant organs through circulation and neural pathways, exerting profound effects on metabolism, endocrine activity, and brain function.⁷⁴⁻⁷⁸ The discovery of these long-range interactions has fundamentally changed the understanding of human physiology, positioning the gut microbiota as a key orchestrator of systemic homeostasis.⁷⁹⁻⁸³

1.2. Gut dysbiosis in Parkinson's disease: clinical and biological implications

Accumulating evidence indicates that people living with PD exhibit consistent and measurable alterations in their intestinal microbiota. These changes, often described as gut dysbiosis, involve shifts in both microbial composition and functionality.⁸⁴⁻⁸⁸ One of the most widely reported findings in PD cohorts is a marked reduction of bacteria capable of producing SCFA, particularly butyrate-producing taxa, including *Faecalibacterium* and *Roseburia*. Since butyrate is crucial for supporting barrier function and promoting anti-inflammatory activity, its depletion may create a permissive environment for chronic inflammation and increased gut permeability.⁸⁹⁻⁹³ Concurrently, several studies have documented a rise in inflammation-associated taxa, including members of the Enterobacteriaceae family and other Gram-negative organisms. These bacteria produce endotoxins and other inflammatory molecules that can activate the immune system at the intestinal level and throughout the body.⁹⁴⁻⁹⁸ The resulting immune activation may contribute to enhanced cytokine production, oxidative stress, and mitochondrial dysfunction, processes strongly associated with PD pathophysiology. These microbial alterations correlate with a number of gastrointestinal symptoms frequently reported by patients with PD, such as constipation, bloating, abdominal discomfort, and altered motility.⁹⁹⁻¹⁰³ More importantly, dysbiosis has been associated with gastrointestinal complaints and also with

the intensity of motor and non-motor manifestations, including cognitive decline, anxiety, depression, and sleep disturbances. These correlations support the idea that gut microbiota changes may influence neurological function through inflammatory, metabolic, and neuroimmune pathways.¹⁰⁴⁻¹⁰⁸

At the biological level, microbial products such as bacterial endotoxins, altered bile acid profiles, and metabolites derived from amino acid fermentation may influence α -synuclein folding and aggregation. Increased intestinal permeability may allow these compounds to reach the systemic circulation, potentially contributing to neuroinflammation and enhancing the vulnerability of dopaminergic neurons. Although the exact temporal sequence remains under investigation, the convergence of clinical and molecular data supports a model in which gut dysbiosis may represent more than a downstream effect of PD, potentially contributing to disease evolution.¹⁰⁹⁻¹¹³

1.3. The gut–brain axis as a mechanistic link

The gut–brain axis is a complex, tightly coordinated network linking the gastrointestinal tract and the central nervous system.¹¹⁴⁻¹¹⁸ This interaction relies on multiple pathways, including the vagus nerve, the enteric nervous system, endocrine signaling, immune mediators, and microbiota-derived metabolites. Together, these mechanisms allow continuous two-way communication between the gut and the brain, thereby enabling the gastrointestinal environment to influence neural activity, behavior, and cognitive functions.¹¹⁹⁻¹²⁶

A major element of this axis is the vagus nerve, which directly links the enteric nervous system to central autonomic nuclei. Experimental studies have shown that vagal pathways can transmit signals related to inflammation, microbial composition, and metabolic changes, influencing regions involved in motor control, mood regulation, and stress responses.¹²⁷⁻¹³⁵ Alterations in vagal signaling have been proposed as a potential route for the propagation of misfolded α -synuclein from the gut to the brain, particularly toward the dorsal motor nucleus of the vagus.

Microbial metabolites provide another important avenue of interaction.¹³⁶⁻¹⁴⁰ SCFA can modulate microglial activation, influence gene expression in neuronal cells, and regulate the permeability of the blood–brain barrier. Likewise, tryptophan metabolites derived from microbial metabolism may affect serotonin pathways, impacting mood, sleep, and gastrointestinal motility, all commonly altered in PD.

Bile acid derivatives and other microbial products can act as signaling molecules, influencing nuclear receptors

and inflammatory cascades in both peripheral tissues and the central nervous system.¹⁴¹⁻¹⁴⁷

The immune pathways also play a crucial role. Dysbiosis can trigger pro-inflammatory cytokine production, activate pattern-recognition receptors, and disrupt regulatory immune networks. These immune responses can subsequently affect central inflammatory processes, contributing to microglial activation and neuronal stress.¹⁴⁸⁻¹⁵⁷ Over time, this neuroinflammatory environment may amplify neurodegenerative cascades, particularly in individuals who already possess genetic or environmental risk factors for PD. The multifaceted nature of the gut–brain axis highlights its potential significance in understanding PD pathogenesis.¹⁵⁸⁻¹⁵⁹ By integrating signals from microbial communities, immune responses, metabolic pathways, and neural circuits, this axis may represent a key interface through which gastrointestinal health influences neurological vulnerability. Understanding these mechanisms is essential for developing diagnostic biomarkers and designing targeted interventions that modulate gut–brain communication in PD.¹⁶⁰⁻¹⁶⁵

In this context, the present systematic review aims to offer additional insights into existing narrative and systematic syntheses by providing an updated and clinically oriented integration of gut microbiota alterations in PD. Specifically, we summarize recurrent microbial patterns across studies while also considering key sources of heterogeneity (e.g., study design, sampling methods, sequencing approaches, and relevant clinical variables) and, where available, their associations with motor and non-motor features. By linking microbiota signatures to clinically meaningful outcomes, this review seeks to inform future efforts toward biomarker discovery for earlier identification and risk stratification, support symptom-based patient stratification, and clarify the rationale for microbiota-targeted therapeutic strategies (dietary interventions, probiotics/prebiotics, and other emerging approaches). Ultimately, delineating consistent microbial signals and their clinical correlates may facilitate translation of descriptive findings to actionable hypotheses for clinical research and patient care.

2. Materials and methods

2.1. Protocol and registration

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and was registered in the International Prospective Register of Systematic Reviews (CRD420251247392). The primary aim of this review is to evaluate the relationship between gut microbiota alterations and PD in human subjects. A protocol was developed prior to initiating the review process to ensure

methodological transparency and reproducibility.

2.2. Search processing

A comprehensive literature search was performed across three major databases, PubMed, Scopus, and Web of Science, from January 1, 2015, to July 1, 2025. The following Boolean string was used: (“Parkinson’s disease” OR “Parkinson disease” OR “PD”) AND (“gut microbiota” OR “gut microbiome” OR “intestinal microbiota” OR “intestinal microbiome” OR dysbiosis OR “gut dysbiosis”) AND (“neuroinflammation” OR “inflammation” OR “gut–brain axis” OR “alpha-synuclein”).

2.3. Inclusion criteria

Three reviewers reviewed all relevant publications that met the following criteria: (i) only human subjects research, (ii) full text, and (iii) scientific studies evaluating the connection between gut microbiota alterations and the onset of PD. The PICOS model was used in accordance with the following steps:

- Criteria: Application in the present study;
- Population: Human subjects;
- Intervention: Evaluation of 16S rRNA sequencing and metaproteomics, microbiota therapy;
- Comparison: Control group;
- Outcome: Evaluation of the connection between gut microbiota alterations and the onset of PD;
- Study design: Randomized controlled trials, prospective observational case-control study, case series, secondary data analysis of Parkinson’s Progression Markers Initiative, open-label non-randomized, multi-omics analysis, case-control study.

2.4. Exclusion criteria

The exclusion criteria were non-English-language articles, ineligible research designs, ineligible outcome measures, ineligible populations, case studies, reviews, and animal studies.

2.5. Data processing

All disagreements among reviewers regarding eligibility or extracted data were resolved through discussion until consensus was reached. The reviewers adhered to standardized extraction procedures to maintain consistency across studies.

2.6. Article identification procedure

Appropriateness was evaluated independently by two reviewers, PB and RL. To increase the number of papers available for full-text analysis, a second manual search was conducted. After evaluating English-language articles that

met the inclusion criteria, duplicates and non-qualifying items were noted and their exclusions explained. The reviewers separately evaluated the article data using a specific electronic form organized into the following categories: authors, year of study, aim of the study, materials and methods, and results.

3. Results

Overall, the included studies consistently reported an altered gut microbial profile in PD compared to controls, with recurrent differences involving taxa linked to SCFA production and intestinal inflammation. While the direction and magnitude of changes varied across cohorts and methodologies, several bacterial groups emerged

repeatedly across studies, suggesting shared dysbiosis patterns that may relate to non-motor symptoms, disease severity, and metabolic readouts. The detailed findings are summarized below and then discussed study-by-study.

The databases Web of Science (269), PubMed (300), and Scopus (250) yielded a total of 819 publications. After de-duplication ($n = 160$), 659 unique records remained. Following an analysis of the abstracts and titles, 138 entries were removed. The remaining 521 papers were then obtained and validated. This method resulted in the elimination of 511 articles that were deemed off-subject. This study includes the qualitative analysis of the 10 final articles (Figure 1). The results of each investigation are shown in Table 1.




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart of the literature search and article inclusion process.
Note: ^aRecords excluded after title and abstract screening.

Table 1. Characteristics of included studies

| Authors | Year | Study type | Aim | Methods | Results |
|--|------|--------------------------------------|--|---|--|
| Lin <i>et al.</i> ¹⁶⁶ | 2019 | Cross-sectional | Evaluate gut microbiota alterations and inflammatory cytokine responses in PD patients | 16S rRNA V3–V4 sequencing of 80 PD vs. 77 controls; plasma cytokines measured; independent validation cohort of 240 subjects (120 PD patients vs. 120 controls) | PD showed increased Verrucomicrobia, <i>Mucispirillum</i> , <i>Porphyromonas</i> , <i>Lactobacillus</i> , <i>Parabacteroides</i> ; controls had higher <i>Prevotella</i> ; Bacteroides correlated with UPDRS III and cytokines TNF-α and IFN-γ |
| Zhang <i>et al.</i> ⁵ | 2020 | Case-control | Compare gut microbiota of PD patients, healthy spouses, and unrelated controls | 16S rRNA sequencing of 63 PD, 63 spouses, 74 controls; clinical phenotyping | Distinct microbiota among groups; inflammation-related taxa increased with Hoehn and Yahr stage. Seven taxa accurately discriminated PD (AUC 0.856) |
| Chen <i>et al.</i> ¹⁰ | 2022 | Observational | Assess relationships between SCFAs, gut microbiota, and PD severity | Fecal + plasma SCFAs quantified via mass spectrometry; metagenomic sequencing of microbiome; MDS-UPDRS & MMSE assessments | PD had ↓ fecal SCFAs but ↑ plasma SCFAs. Reduced fecal SCFAs correlated with motor severity; SCFA-producing bacteria lost their correlation with SCFA levels in PD |
| Lin <i>et al.</i> ¹⁶⁷ | 2025 | Cross-sectional | Evaluate gut microbiota differences in PD patients with and without ICDs | 16S rRNA sequencing of 191 PD patients (14 ICD+ vs. 177 ICD–) | No diversity differences; ICD patients enriched in <i>Methanobrevibacter</i> and <i>Intestinimonas butyriciproducens</i> ; functional pathways related to xenobiotic degradation were elevated |
| Pietrucci <i>et al.</i> ¹⁶⁸ | 2020 | Machine-learning study | Identify microbial signatures predictive of PD | Analysis of 846 metagenomic samples; ML algorithms (random forest, neural networks, SVMs) | Random forest best predicted PD status; 22 bacterial families identified as key discriminators |
| Lee <i>et al.</i> ¹⁶⁹ | 2025 | Prospective observational (protocol) | Analyze effects of acupuncture/moxibustion on gut microbiome and PD symptoms | Analysis of 60 PD patients + 20 controls; 12-week acupuncture/moxibustion; repeated microbiome sequencing and clinical assessments | Study ongoing; aims to correlate microbiome modulation with motor and non-motor symptom changes |
| Mao <i>et al.</i> ¹⁷⁰ | 2021 | Cross-sectional | Describe microbiome alterations in PD patients in Central China | Shotgun metagenomic sequencing of 39 PD patients vs. 39 healthy spouses | PD showed enrichment in <i>Bilophila wadsworthia</i> , <i>Klebsiella</i> , and <i>Parasutterella</i> correlated with disease severity; <i>Prevotella</i> negatively correlated; functional pathways related to BCAA metabolism altered |
| Kwon <i>et al.</i> ¹⁷¹ | 2024 | Observational | Examine associations between diet and gut microbiota in PD patients | Analysis of 85 PD patients; 16S sequencing; dietary quality assessed via HEI-2015 | Higher fiber led to ↑ butyrate-producers (<i>Butyricoccus</i> , <i>Coprococcus</i>). High sugar led to ↑ <i>Klebsiella</i> and pro-inflammatory taxa. Healthy diet associated with reduced LPS-related genes |

(cont'd...)

Table 1. (Continued)

| Authors | Year | Study type | Aim | Methods | Results |
|-------------------------------------|------|-------------------------------|---|--|--|
| Zapała <i>et al.</i> ¹⁷² | 2021 | Cohort study | Compare the microbiota of PD patients and healthy controls | Analysis of 27 PD patients on levodopa vs. 44 matched controls; NGS | PD had ↑ <i>Bacteroides</i> , <i>Corynebacteria</i> , <i>Deltaproteobacteria</i> , <i>Butyricimonas</i> , <i>Flavonifractor</i> , <i>Akkermansia muciniphila</i> , and <i>Eubacterium bifforme</i> |
| Becker <i>et al.</i> ⁵⁸ | 2022 | Interventional clinical trial | Assess effects of resistant starch on gut microbiota and symptoms | Analysis of 8-week RS intervention in PD; metagenomics; fecal SCFA and calprotectin measured | ↑ fecal butyrate and ↓ calprotectin in PD + RS group; improved non-motor symptoms; stable α- and β- diversity across groups |

Notes: ↑ Increased; ↓ Decreased.

Abbreviations: AUC: Area under the curve; BCAA: Branched-chain amino acid; HEI: Healthy eating index; ICDs: Impulse control disorders; IFN: Interferon; LPS: Lipopolysaccharide; PD: Parkinson's disease; RS: Resistant starch; SCFA: Short-chain fatty acid; SVMs: Support vector machines; TNF: Tumor necrosis factor; NGS: Next-generation sequencing; UPDRS III: Unified Parkinson's Disease Rating Scale, Part III.

3.1. Quality assessment

Overall, the included studies showed a predominantly low-to-moderate risk of bias across the Risk of Bias in Non-randomized Studies of Intervention (ROBINS-I) domains, with several concerns mainly related to confounding and participant selection (Table 2).

The quality of the papers included was evaluated by two reviewers, PB and RL, using the ROBINS-I approach. In non-randomized studies evaluating the health effects of two or more medications, ROBINS-I was created to assess the risk of bias. A bias degree was assigned to each of the seven criteria that were examined. In the event of a disagreement, the third reviewer, FI, was consulted until a resolution was reached. Any disagreements or disputes among reviewers were resolved through dialogue and consensus-building to improve the objectivity and consistency of the evaluations. A third reviewer made the final decision in cases of disagreement. Identifying the advantages and disadvantages of the evidence base helped provide a more accurate evaluation of the results' quality and dependability. By accounting for the likelihood of bias, we were able to draw informed interpretations and conclusions based on the evidence presented.

4. Discussion

4.1. General overview of microbiota alterations in patients with Parkinson's disease

The 10 studies selected for this review provide a robust, multidimensional understanding of gut microbiota alterations in PD, confirming dysbiosis as a recurrent,

clinically meaningful signature across PD cohorts.¹⁶⁷⁻¹⁶⁸

Unlike earlier frameworks that relied on non-validated datasets, this discussion integrates only peer-reviewed articles using standardized sequencing or metabolomic approaches, ensuring methodological consistency and reliable interpretation.¹⁶⁷⁻¹⁶⁹ Collectively, these studies demonstrate that dysbiosis is not an incidental by-product of PD but a component tightly associated with disease phenotype and systemic inflammatory responses.¹⁷⁰⁻¹⁷¹ Across the included literature, a reduction of SCFA-producing genera, particularly *Faecalibacterium*, *Roseburia*, and *Butyricoccus*, is consistently reported, accompanied by an increase in inflammation-associated microbes, such as *Enterobacteriaceae* and *Akkermansia*.¹⁷²

These compositional shifts are likely to contribute to impaired intestinal barrier integrity, increased endotoxin translocation, and chronic low-grade systemic inflammation, all of which are known to influence neurodegenerative pathways relevant to PD.¹⁷³⁻¹⁸²

Mechanistically, several gut-brain axis routes may plausibly link dysbiosis to neurodegenerative processes in PD. Reduced SCFA availability (particularly butyrate) may weaken epithelial integrity and immune tolerance, thereby increasing intestinal permeability and facilitating luminal endotoxin exposure. In parallel, expansion of pro-inflammatory taxa may enhance lipopolysaccharide-driven immune activation, promoting peripheral cytokine signaling and sustained low-grade systemic inflammation. These systemic signals may contribute to microglial priming and neuroinflammatory cascades, which are recognized contributors to neurodegenerative

Table 2. Summary of the main findings of the included studies investigating gut dysbiosis in patients with Parkinson's disease

| Authors | D1 | D2 | D3 | D4 | D5 | D6 | D7 | Overall |
|--|----|----|----|----|----|----|----|---------|
| Lin <i>et al.</i> ¹⁶⁶ | | | | | | | | |
| Zhang <i>et al.</i> ⁵ | | | | | | | | |
| Chen <i>et al.</i> ¹⁰ | | | | | | | | |
| Lin <i>et al.</i> ¹⁶⁷ | | | | | | | | |
| Pietrucci <i>et al.</i> ¹⁶⁸ | | | | | | | | |
| Lee <i>et al.</i> ¹⁶⁹ | | | | | | | | |
| Mao <i>et al.</i> ¹⁷⁰ | | | | | | | | |
| Kwon <i>et al.</i> ¹⁷¹ | | | | | | | | |
| Zapała <i>et al.</i> ¹⁷² | | | | | | | | |
| Becker <i>et al.</i> ⁵⁸ | | | | | | | | |

Notes: very high; high; some concerns; low; no information; D1: Bias due to confounding; D2: Bias arising from the measurement of the exposure; D3: Bias in the selection of participants in the study (or into the analysis); D4: Bias due to post-exposure interventions; D5: Bias due to missing data; D6: Bias arising from the measurement of the outcome; D7: Bias in selection of the reported result.

vulnerability. Although most available clinical studies are observational and do not establish causality, these convergent mechanisms provide a biologically plausible framework through which gut microbial alterations could interact with α -synuclein-related pathology and disease progression, warranting confirmation in longitudinal and interventional cohorts.¹⁸³⁻¹⁹⁰

Taken together, these recurrent dysbiosis patterns support the evaluation of gut microbiota profiles as adjunct biomarkers for earlier identification and patient

stratification in PD, pending validation in standardized longitudinal cohorts.

4.2. Microbial composition signatures and cross-population consistency

To support cross-population comparisons more transparently, Table 3 summarizes cohort geography (country/region), available contextual and dietary information, reported ethnicity, and the main taxa increased or decreased across the included PD studies. When such information was not reported in the original articles, this is

Table 3. Context of cross-population cohorts and main microbiome findings from the included Parkinson's disease studies

| Study | Country/ region | Sample size (PD/controls) | Ethnicity | Diet/context | Method | Main taxa ↑ in PD | Main taxa ↓ in PD | Key clinical/ biomarker links |
|--|--------------------|--|-----------|---------------------------------|---|---|----------------------|--|
| Lin <i>et al.</i> ¹⁶⁶ | NR | 80/77 (another validation cohort: 120/120) | NR | NR | 16S rRNA V3-V4; plasma cytokines | <i>Verrucomicrobia</i> , <i>Mucispirillum</i> , <i>Porphyromonas</i> , <i>Lactobacillus</i> , and <i>Parabacteroides</i> | <i>Prevotella</i> | Bacteroides correlated with UPDRS III, TNF- α, and IFN-γ |
| Zhang <i>et al.</i> ⁵ | NR | 63/74 (+63 spouses) | NR | Shared household environment | 16S rRNA sequencing | Inflammation-related taxa ↑ with H&Y stage | NR | A total of 7 taxa discriminated PD (AUC 0.856) |
| Pietrucci <i>et al.</i> ¹⁶⁸ | NR | 846 samples | NR | NR | Metagenomics + ML (RF, NN, SVM) | 22 bacterial families (not listed) | NR | RF best classifier of PD status |
| Mao <i>et al.</i> ¹⁷⁰ | Central China | 39/39 (spouses) | NR | Shared environment (spouses) | Shotgun metagenomics | <i>Bifidobacterium wadsworthia</i> , <i>Klebsiella</i> , and <i>Parasutterella</i> | <i>Prevotella</i> | Severity correlated; altered BCAA pathways |
| Zapala <i>et al.</i> ¹⁷² | NR | 27/44 | NR | Levodopa users | NGS sequencing | <i>Bacteroides</i> , <i>Corynebacteria</i> , <i>Deltaproteobacteria</i> , <i>Butyrivibrio</i> , <i>Flavobacterium</i> , <i>Akkermansia</i> <i>muciniphila</i> , and <i>Eubacterium biforme</i> | NR | NR |
| Chen <i>et al.</i> ¹⁰ | NR | NR | NR | NR | SCFAs (MS); metagenomics; UPDRS, MMSE | NR | NR | ↓ fecal SCFAs ↑ plasma SCFAs; motor severity correlation |
| Becker <i>et al.</i> ⁵⁸ | NR | NR | NR | Resistant starch (8 weeks) | Metagenomics; SCFAs; calprotectin | NR | NR | ↑ butyrate, ↓ calprotectin; improved non-motor symptoms |
| Kwon <i>et al.</i> ¹⁷¹ | NR | 85/NR | NR | Diet quality (HEI - 2015) | 16S rRNA sequencing | <i>Butyrivibrio</i> and <i>Coprococcus</i> (induced by high fiber) | NR | High sugar ↑ <i>Klebsiella</i> ; LPS-related genes ↓ with a healthy diet |
| Lin <i>et al.</i> ¹⁶⁷ | NR | 191/177 (ICD+ vs. ICD-) | NR | NR | 16S rRNA sequencing | <i>Methanobrevibacter</i> and <i>Intestinimonas</i> ; produced butyric acid | NR | Xenobiotic degradation pathways ↑ |
| Lee <i>et al.</i> ¹⁶⁹ | NR | 60/20 | NR | Acupuncture/moxibustion | Repeated microbiome sequencing | NR | NR | Study ongoing |

Notes: ↑ Increased; ↓ Decreased; Dietary habits and ethnicity were inconsistently reported across the included studies.

Abbreviations: AUC: Area under the curve; BCAA: Branched-chain amino acid; H&Y stage: Hoehn and Yahr stage; HEI: Healthy eating index; ICDs: Impulse control disorders; IFN: Interferon; LPS: Lipopolysaccharide; MMSE: Mini-mental state examination; ML: Machine learning; MS: Mass spectrometry; NN: Neural network; NR: Not reported; PD: Parkinson's disease; RF: Random forest; RS: Resistant starch; SCFA: Short-chain fatty acid; SVMs: Support vector machines; TNF: Tumor necrosis factor; NGS: Next-generation sequencing; UPDRS: Unified Parkinson's Disease Rating Scale.

indicated as not reported. For instance, Lin *et al.*¹⁶⁶ reported increased abundance of *Lactobacillus*, *Parabacteroides*, and *Verrucomicrobia*, together with reduced *Prevotella*, a pattern replicated in multiple independent cohorts, although the magnitude and direction of some taxa varied across populations and analytical pipelines.

Importantly, these compositional changes were associated with systemic immune alterations, including elevated levels of tumor necrosis factor- α and interferon- γ , linking gut dysbiosis to inflammatory pathways implicated in PD pathophysiology.¹⁹¹⁻¹⁹³ Similarly, Zapala *et al.*¹⁷² and Mao *et al.*¹⁷⁰ identified increased abundance of *Akkermansia muciniphila* and *Bifidobacterium wadsworthia*, taxa involved in mucin degradation and bile resistance.

Together, these findings reinforce the concept of a shared “pro-inflammatory enterotype” in PD, largely independent of geographic or environmental background. Cross-population consistency of key microbial signals strengthens their translational potential and supports future use in risk stratification and prognostic modeling, provided findings are externally validated using harmonized sampling and analytical pipelines.

4.3. Functional and metabolomic alterations

Functional alterations of the microbiome, particularly in SCFA metabolism, have emerged as central features of dysbiosis in PD.¹⁹⁴⁻²⁰³ Chen *et al.*¹⁰ reported reduced fecal SCFA concentrations in PD patients, especially butyrate, despite increased circulating levels, suggesting impaired mucosal uptake and epithelial dysfunction.

Lower fecal SCFA concentrations are correlated with more severe motor impairment and poorer cognitive scores, supporting a mechanistic link between microbial metabolites and neural function.²⁰⁴ The interventional RESISTA-PD trial conducted by Becker *et al.*⁵⁸ further demonstrated that resistant starch supplementation increases fecal butyrate, reduces intestinal inflammation, and improves gastrointestinal and non-motor symptoms in PD. This highlights the therapeutic potential of restoring SCFA-producing bacterial communities.²⁰⁵ Environmental influences, including diet, also play a major role in determining microbiota composition in PD. Zhang *et al.*⁵ showed that even when PD patients live with healthy spouses, their microbiota profiles remain significantly distinct, indicating that dysbiosis is not solely driven by shared dietary or environmental factors.

Kwon *et al.*¹⁷¹ found that higher fiber consumption is associated with greater abundance of beneficial butyrate-producing taxa, while high sugar consumption promotes proliferation of *Klebsiella* and other pro-inflammatory organisms.

This suggests that dietary interventions could complement pharmacological therapy by creating a gut environment less conducive to inflammatory and neurodegenerative processes. Convergent functional and metabolomic findings provide a strong rationale for microbiota-targeted dietary and metabolic interventions as adjunctive strategies in PD management.

More broadly, human studies indicate that microbiome-targeted interventions can be clinically actionable in selected conditions, providing a translational precedent for microbiota-based therapies.^{58,169-172} In PD, however, interventional evidence remains limited and heterogeneous, and adequately powered trials with harmonized clinical and microbiome endpoints are required before routine clinical adoption.

4.4. Gut dysbiosis and non-motor symptoms in Parkinson's disease

Non-motor features—such as cognitive deficits, mood symptoms, and autonomic dysfunction—show meaningful associations with dysbiosis.¹⁷³⁻¹⁸² Lin *et al.*¹⁶⁷ described distinct microbiome patterns among PD patients with impulse-control disorders, particularly increased *Methanobrevibacter* and *Intestinimonas butyriciproducens*.

Other studies identified links between microbial alterations and gastrointestinal dysfunction, anxiety, sleep disturbances, and cognitive decline, suggesting that gut microbes influence both the central and enteric nervous systems.¹⁸³⁻¹⁹⁰ These associations reinforce the concept that gut microbiota act across a wide clinical spectrum in PD, extending beyond motor impairment.¹⁹¹⁻¹⁹²

Machine-learning approaches illustrate the diagnostic potential of microbial biomarkers.¹⁹³⁻¹⁹⁷ Pietrucci *et al.*¹⁶⁸ demonstrated that microbial signatures can classify PD with high accuracy using random forests, support vector machines, and neural networks.

At present, microbiome-based diagnostics for PD remain investigational and are unavailable as approved clinical tests. Despite advances in metagenomics and bioinformatic approaches, translation into clinical diagnostics is limited by substantial inter-cohort heterogeneity (diet, medication use, constipation severity, and geography), methodological variability in sampling and sequencing, batch effects, and insufficient external validation across independent populations.

While preliminary, these data suggest that microbiome-based diagnostic tools may complement current clinical scales and eventually contribute to early detection.¹⁹⁵⁻²⁰⁴ Future work should aim to standardize microbial classifiers to ensure reproducibility across studies and cohorts.

Microbiota profiles may support symptom-based phenotyping and contribute to future diagnostic and prognostic frameworks, particularly for non-motor manifestations of PD.

4.5. Limitations, future directions, and clinical implications

Despite promising findings, several limitations are consistently noted across studies. Sample sizes are often modest, reducing statistical power and hindering detection of smaller but clinically meaningful effects. Heterogeneity in sequencing methods (16S vs. shotgun), data processing pipelines, and confounding factors, such as medication use, constipation severity, and dietary intake, limits comparability across studies. Longitudinal studies remain scarce, hindering our ability to determine causality or assess whether dysbiosis precedes PD onset.

Future research should prioritize large, multi-center, longitudinal cohorts with harmonized methodologies, dietary control, and integrated host biomarker profiling. Gut-focused interventions, including prebiotics, probiotics, resistant starch, and microbiota-centered non-pharmacological interventions, represent promising avenues for modifying disease progression. Ultimately, a more nuanced understanding of gut-brain interactions may enable personalized therapeutic approaches for PD based on individual microbial signatures.

Although the microbiome-PD literature has expanded over the last decade, only a limited number of studies met our predefined eligibility criteria, which prioritized human cohorts, original peer-reviewed data, standardized microbiome/metabolomic methodologies, and sufficient reporting for extraction and comparison. Numerous publications were excluded because they were narrative reviews, preclinical studies, conference abstracts, or lacked extractable and methodologically comparable microbiome outcomes. This limited yield underscores the need for harmonized protocols, adequate sample sizes, and longitudinal designs to improve reproducibility and clinical translation; nevertheless, synthesizing the best available standardized evidence remains valuable to delineate the most recurrent signals and to guide future study design.

5. Conclusion

This systematic review underscores an expanding body of literature linking changes in the gut microbiota to the clinical expression and progression of PD. Across the 10 selected studies, consistent dysbiotic patterns emerged, particularly lower abundance of SCFA-producing bacteria and higher levels of taxa linked to inflammation and mucosal barrier disruption. Importantly, several studies demonstrated

meaningful associations between microbial imbalances and both motor and non-motor manifestations, including gastrointestinal impairment, autonomic impairment, and behavioral disturbances, suggesting a broad impact of gut dysbiosis on the clinical phenotype of PD.

The inclusion of interventional studies provided further insight into the potential therapeutic relevance of the gut microbiota. Approaches such as resistant starch supplementation and acupuncture demonstrated the capacity to modulate microbial composition and improve select clinical outcomes, while machine-learning analyses offered promising evidence for the development of microbiome-driven diagnostic tools. Collectively, these findings highlight the gut-brain axis as a promising frontier for mechanistic insight and therapeutic innovation in PD.

Nevertheless, the limitations identified across the selected studies emphasize the need for more rigorous and standardized research. Large-scale, longitudinal studies with harmonized microbiota sequencing methods, comprehensive assessment of confounders, and integration of host biological markers will be critical for determining whether microbiota alterations are causal contributors to PD or secondary phenomena. As the field progresses, microbiota-centered diagnostics and targeted interventions may ultimately support more personalized and effective management strategies for individuals with PD. By synthesizing the most consistent microbiota and metabolomic alterations in PD, this review provides clinicians and researchers with a concise evidence base to support patient stratification hypotheses and to guide the design of standardized, longitudinal, and interventional studies.

Acknowledgments

None.

Funding

None.

Conflict of interest

The authors declare they have no competing interests.

Author contributions

Conceptualization: Alessio Danilo Inchingolo, Gianna Dipalma

Data curation: Gianna Dipalma, Cinzia Maspero, Franceska Vinjoli

Formal analysis: Angelo Michele Inchingolo, Cinzia Maspero, Franceska Vinjoli

Methodology: Grazia Marinelli, Kenan Ferati

Project administration: Alessio Danilo Inchingolo, Ioana Roxana Bordea, Arberesha Bexheti- Ferati, Angelo Michele Inchingolo

Resources: Alessio Danilo Inchingolo, Andrea Palermo, Giuseppe Minervini, Angelo Michele Inchingolo

Software: Andrea Palermo, Ioana Roxana Bordea

Supervision: Francesco Inchingolo, Kenan Ferati, Gianna Dipalma

Validation: Francesco Inchingolo, Arberesha Bexheti-Ferati, Rosalba Lagioia, Paola Bassi
Investigation: Rosalba Lagioia, Antonio Rizzo, Francesco Inchingolo, Paola Bassi

Visualization: Angelo Michele Inchingolo, Grazia Marinelli, Gianna Dipalma

Writing—original draft: Giuseppe Minervini, Rosalba Lagioia, Antonio Rizzo, Paola Bassi

Writing—review & editing: Francesco Inchingolo, Alessio Danilo Inchingolo, Andrea Palermo

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data

Not applicable.

References

1. Cabanillas-Lazo M, Quispe-Vicuña C, Barja-Ore J, *et al.* A 10-Year Bibliometric Analysis of Global Research on Gut Microbiota and Parkinson's Disease: Characteristics, Impact, and Trends. *Biomed Res Int.* 2022;2022:4144781. doi: 10.1155/2022/4144781
2. Aktas B, Aslim B, Ozdemir DA. A Neurotherapeutic Approach with Lactaseibacillus Rhamnosus E9 on Gut Microbiota and Intestinal Barrier in MPTP-Induced Mouse Model of Parkinson's Disease. *Sci Rep.* 2024;14(1):15460. doi: 10.1038/s41598-024-65061-w
3. Vidal-Martinez G, Chin B, *et al.* A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxoy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models. *J Parkinsons Dis.* 2020;10(1):185-192. doi: 10.3233/JPD-191693
4. Fu SC, Lee CH, Hsieh YC, Wu PH, Lin SH, Wang H. A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease. *Front Cell Infect Microbiol.* 2022;12:837019. doi: 10.3389/fcimb.2022.837019
5. Zhang F, Yue L, Fang X, *et al.* Altered Gut Microbiota in Parkinson's Disease Patients/Healthy Spouses and Its Association with Clinical Features. *Parkinsonism Relat Disord.* 2020;81:84-88. doi: 10.1016/j.parkreldis.2020.10.034
6. Zhang K, Paul K, Jacobs JP, *et al.* Ambient Long-Term Exposure to Organophosphorus Pesticides and the Human Gut Microbiome: An Observational Study. *Environ Health.* 2024;23(1):41. doi: 10.1186/s12940-024-01078-y
7. Hall DA, Voigt RM, Cantu-Jungles TM, *et al.* An Open Label, Non-Randomized Study Assessing a Prebiotic Fiber Intervention in a Small Cohort of Parkinson's Disease Participants. *Nat Commun.* 2023;14(1):926. doi: 10.1038/s41467-023-36497-x
8. Alfonsetti M, Castelli V, d'Angelo M. Are We What We Eat? Impact of Diet on the Gut-Brain Axis in Parkinson's Disease. *Nutrients.* 2022;14(2):380. doi: 10.3390/nu14020380
9. Bai F, You L, Lei H, Li X. Association between Increased and Decreased Gut Microbiota Abundance and Parkinson's Disease: A Systematic Review and Subgroup Meta-Analysis. *Exp Gerontol.* 2024;191:112444. doi: 10.1016/j.exger.2024.112444
10. Chen SJ, Chen CC, Liao HY, *et al.* Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease. *Neurology.* 2022;98(8):e848-e858. doi: 10.1212/WNL.00000000000013225
11. Chen ZJ, Liang CY, Yang LQ, *et al.* Association of Parkinson's Disease With Microbes and Microbiological Therapy. *Front Cell Infect Microbiol.* 2021;11:619354. doi: 10.3389/fcimb.2021.619354
12. Chen C, Liao J, Xia Y, *et al.* Gut Microbiota Regulate Alzheimer's Disease Pathologies and Cognitive Disorders via PUFA-Associated Neuroinflammation. *Gut.* 2022;71(11):2233-2252. doi: 10.1136/gutjnl-2021-326269
13. Li Z, Zhu H, Guo Y, Du X, Qin C. Gut Microbiota Regulate Cognitive Deficits and Amyloid Deposition in a Model of Alzheimer's Disease. *J Neurochem.* 2020;155(4):448-461. doi: 10.1111/jnc.15031
14. Xie J, Bruggeman A, De Nolf C, *et al.* Gut Microbiota Regulates Blood-Cerebrospinal Fluid Barrier Function and Aβ Pathology. *EMBO J.* 2023;42(17):e111515. doi: 10.15252/embj.2022111515
15. Chen Y, Li Y, Fan Y, Chen S, *et al.* Gut Microbiota-Driven

- Metabolic Alterations Reveal Gut-Brain Communication in Alzheimer's Disease Model Mice. *Gut Microbes*. 2024;16(1):2302310.
doi: 10.1080/19490976.2024.2302310
16. Luo YX, Yang LL, Yao XQ. Gut Microbiota-Host Lipid Crosstalk in Alzheimer's Disease: Implications for Disease Progression and Therapeutics. *Mol Neurodegener*. 2024;19(1):35.
doi: 10.1186/s13024-024-00720-0
17. Molinero N, Antón-Fernández A, Hernández F, *et al*. Gut Microbiota, an Additional Hallmark of Human Aging and Neurodegeneration. *Neuroscience*. 2023;518:141-161.
doi: 10.1016/j.neuroscience.2023.02.014
18. Khan MS, Ikram M, Park JS, Park TJ, Kim MO. Gut Microbiota, Its Role in Induction of Alzheimer's Disease Pathology, and Possible Therapeutic Interventions: Special Focus on Anthocyanins. *Cells*. 2020;9(4):853.
doi: 10.3390/cells9040853
19. Logan K, Ng TKS, Wee HN, Ching J. Gut-Brain Axis through the Lens of Gut Microbiota and Their Relationships with Alzheimer's Disease Pathology: Review and Recommendations. *Mech Ageing Dev*. 2023;211:111787.
doi: 10.1016/j.mad.2023.111787
20. Zhang J, Hao J, Liu R, *et al*. Hawthorn Flavonoid Ameliorates Cognitive Deficit in Mice with Alzheimer's Disease by Increasing the Levels of Bifidobacteriales in Gut Microbiota and Docosapentaenoic Acid in Serum Metabolites. *Food Funct*. 2022;13(23):12371-12382.
doi: 10.1039/d2fo02871a
21. Guan Y, Shi D, Wang S, *et al*. Hericium Coralloides Ameliorates Alzheimer's Disease Pathologies and Cognitive Disorders by Activating Nrf2 Signaling and Regulating Gut Microbiota. *Nutrients*. 2023;15(17):3799.
doi: 10.3390/nu15173799
22. Gorecka-Mazur A, Krygowska-Wajs A, Furgala A, *et al*. Associations between Gut Microbiota Characteristics and Non-Motor Symptoms Following Pharmacological and Surgical Treatments in Parkinson's Disease Patients. *Neurogastroenterol Motil*. 2024;36(8):e14846.
doi: 10.1111/nmo.14846
23. Arikian M, Yildiz Z, Kahraman Demir T, *et al*. Axillary Microbiota Is Associated with Cognitive Impairment in Parkinson's Disease Patients. *Microbiol Spectr*. 2022;10(1):e0235821.
doi: 10.1128/spectrum.02358-21
24. Montanari M, Imbriani P, Bonsi P, Martella G, Peppe A. Beyond the Microbiota: Understanding the Role of the Enteric Nervous System in Parkinson's Disease from Mice to Human. *Biomedicines*. 2023;11(6):1560.
doi: 10.3390/biomedicines11061560
25. Liu TW, Chen CM, Chang KH. Biomarker of Neuroinflammation in Parkinson's Disease. *Int J Mol Sci*. 2022;23(8):4148.
doi: 10.3390/ijms23084148
26. Dodiya HB, Forsyth CB, Voigt RM, *et al*. Chronic Stress-Induced Gut Dysfunction Exacerbates Parkinson's Disease Phenotype and Pathology in a Rotenone-Induced Mouse Model of Parkinson's Disease. *Neurobiol Dis*. 2020;135:104352.
doi: 10.1016/j.nbd.2018.12.012
27. Zhang M, Wang H, Xue L, Yang X. Advances in fecal microbiota transplantation for treatment of Parkinson's disease. *Sheng Wu Gong Cheng Xue Bao*. 2021;37:3812-3819.
doi: 10.13345/j.cjb.200770
28. Lei W, Cheng Y, Gao J, Liu X, *et al*. Akkermansia Muciniphila in Neuropsychiatric Disorders: Friend or Foe? *Front Cell Infect Microbiol*. 2023;13:1224155.
doi: 10.3389/fcimb.2023.1224155
29. Vascellari S, Melis M, Palmas V, *et al*. Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes. *Biomolecules*. 2021;11(2):144.
doi: 10.3390/biom11020144
30. Liu X, Du ZR, Wang X, *et al*. Colonic Dopaminergic Neurons Changed Reversely With Those in the Midbrain via Gut Microbiota-Mediated Autophagy in a Chronic Parkinson's Disease Mice Model. *Front Aging Neurosci*. 2021;13:649627.
doi: 10.3389/fnagi.2021.649627
31. He ZQ, Huan PF, Wang L, He JC. Compound Dihuang Granule Changes Gut Microbiota of MPTP-Induced Parkinson's Disease Mice via Inhibiting TLR4/NF-κB Signaling. *Neurochem Res*. 2023;48(12):3610-3624.
doi: 10.1007/s11064-023-04004-9
32. Shao Y, Li T, Liu Z, *et al*. Comprehensive Metabolic Profiling of Parkinson's Disease by Liquid Chromatography-Mass Spectrometry. *Mol Neurodegener*. 2021;16(1):4.
doi: 10.1186/s13024-021-00425-8
33. Domínguez Rojo N, Blanco Benítez M, Cava R, Fuentes JM, Canales Cortés S, González Polo RA. Convergence of Neuroinflammation, Microbiota, and Parkinson's Disease: Therapeutic Insights and Prospects. *Int J Mol Sci*. 2024;25(21):11629.
doi: 10.3390/ijms252111629
34. Alam MZ, Alam Q, Kamal MA, Abuzenadah AM, Haque A. A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer's Disease Pathogenicity: An Update. *CNS Neurol Disord Drug Targets*. 2014;13(3):383-390.

doi: 10.2174/18715273113126660151

35. Tettevi EJ, Maina M, Simpong DL, Osei-Atweneboana MY, Ocloo A. A Review of African Medicinal Plants and Functional Foods for the Management of Alzheimer's Disease-Related Phenotypes, Treatment of HSV-1 Infection and/or Improvement of Gut Microbiota. *J Evid Based Integr Med*. 2022;27:2515690X221114657.
doi: 10.1177/2515690X221114657
36. Sun M, Ma K, Wen J, *et al*. A Review of the Brain-Gut-Microbiome Axis and the Potential Role of Microbiota in Alzheimer's Disease. *J Alzheimers Dis*. 2020;73(3):849-865.
doi: 10.3233/JAD-190872
37. Salminen A. Activation of Aryl Hydrocarbon Receptor (AhR) in Alzheimer's Disease: Role of Tryptophan Metabolites Generated by Gut Host-Microbiota. *J Mol Med*. 2023;101(3):201-222.
doi: 10.1007/s00109-023-02289-5
38. Santacroce L, Sardaro N, Topi S, *et al*. The pivotal role of oral microbiota in health and disease. *J Biol Regul Homeost Agents*. 2020;34(2):733-737.
doi: 10.23812/20-127-L-45. PMID: 32492992
39. Khedr EM, Omeran N, Karam-Allah Ramadan H, Ahmed GK, Abdelwarith AM. Alteration of Gut Microbiota in Alzheimer's Disease and Their Relation to the Cognitive Impairment. *J Alzheimers Dis*. 2022;88(3):1103-1114.
doi: 10.3233/JAD-220176
40. Wei Z, Li D, Shi J. Alterations of Spatial Memory and Gut Microbiota Composition in Alzheimer's Disease Triple-Transgenic Mice at 3, 6, and 9 Months of Age. *Am J Alzheimers Dis Other Dement*. 2023;38:15333175231174193.
doi: 10.1177/15333175231174193
41. MahmoudianDehkordi S, Arnold M, Nho K, *et al*. Altered Bile Acid Profile Associates with Cognitive Impairment in Alzheimer's Disease-An Emerging Role for Gut Microbiome. *Alzheimers Dement*. 2019;15(1):76-92.
doi: 10.1016/j.jalz.2018.07.217
42. Zhu Z, Ma X, Wu J, *et al*. Altered Gut Microbiota and Its Clinical Relevance in Mild Cognitive Impairment and Alzheimer's Disease: Shanghai Aging Study and Shanghai Memory Study. *Nutrients*. 2022;14(19):3959.
doi: 10.3390/nu14193959
43. Liu P, Wu L, Peng G, *et al*. Altered Microbiomes Distinguish Alzheimer's Disease from Amnesic Mild Cognitive Impairment and Health in a Chinese Cohort. *Brain Behav Immun*. 2019;80:633-643.
doi: 10.1016/j.bbi.2019.05.008
44. Liu X, Liu Y, Liu J, *et al*. Correlation between the Gut Microbiome and Neurodegenerative Diseases: A Review of Metagenomics Evidence. *Neural Regen Res*. 2024;19(4):833-845.
doi: 10.4103/1673-5374.382223
45. Cui C, Han Y, Li H, Yu H, Zhang B, Li G. Curcumin-Driven Reprogramming of the Gut Microbiota and Metabolome Ameliorates Motor Deficits and Neuroinflammation in a Mouse Model of Parkinson's Disease. *Front Cell Infect Microbiol*. 2022;12:887407.
doi: 10.3389/fcimb.2022.887407
46. Chang CH, Lin CH, Lane HY. D-Glutamate and Gut Microbiota in Alzheimer's Disease. *Int J Mol Sci*. 2020;21(8):2676.
doi: 10.3390/ijms21082676
47. Zhang W, Ding L, Zhang M, *et al*. Dietary Intake of α -Ketoglutarate Ameliorates α -Synuclein Pathology in Mouse Models of Parkinson's Disease. *Cell Mol Life Sci*. 2023;80(6):155.
doi: 10.1007/s00018-023-04807-7
48. Wang Z, Cui Y, Wen L, *et al*. Dietary Restriction against Parkinson's Disease: What We Know So Far. *Nutrients*. 2022;14(19):4108.
doi: 10.3390/nu14194108
49. Park DG, Kang W, Shin IJ, *et al*. Difference in Gut Microbial Dysbiotic Patterns between Body-First and Brain-First Parkinson's Disease. *Neurobiol Dis*. 2024;201:106655.
doi: 10.1016/j.nbd.2024.106655
50. Caiyun M, Hebao W, Wenhao Y, Changqing L, Changqing L, Xiaojiang Z. Dissecting Causal Links Between Gut Microbiota, Inflammatory Cytokines, and Parkinson's Disease: A Mendelian Randomization Study. *Brain Behav*. 2024;14(11):e70169.
doi: 10.1002/brb3.70169
51. Cilia R, Piatti M, Cereda E, *et al*. Does Gut Microbiota Influence the Course of Parkinson's Disease? A 3-Year Prospective Exploratory Study in de Novo Patients. *J Parkinsons Dis*. 2021;11(1):159-170.
doi: 10.3233/JPD-202297
52. Yu J, Meng J, Qin Z, *et al*. Dysbiosis of Gut Microbiota Inhibits NMNAT2 to Promote Neurobehavioral Deficits and Oxidative Stress Response in the 6-OHDA-Lesioned Rat Model of Parkinson's Disease. *J Neuroinflammation*. 2023;20(1):117.
doi: 10.1186/s12974-023-02782-1
53. Peterson CT. Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics. *J Evid Based Integr Med*. 2020;25:2515690X20957225.

- doi: 10.1177/2515690X20957225
54. Kaur G, Behl T, Bungau S, *et al.* Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson's Disease. *Curr Neuroparmacol.* 2021;19(2):233-247.
doi: 10.2174/1570159X18666200606233050
55. Yang X, He X, Xu S, *et al.* Effect of Lactacaseibacillus Paracasei Strain Shirota Supplementation on Clinical Responses and Gut Microbiome in Parkinson's Disease. *Food Funct.* 2023;14(15):6828-6839.
doi: 10.1039/d3fo00728f
56. Radisavljevic N, Cirstea M, Bauer K, *et al.* Effects of Gut Microbiota Alterations on Motor, Gastrointestinal, and Behavioral Phenotype in a Mouse Model of Parkinson's Disease. *J Parkinsons Dis.* 2022;12(5):1479-1495.
doi: 10.3233/JPD-223165
57. Chui ZSW, Chan LML, Zhang EWH, *et al.* Effects of Microbiome-Based Interventions on Neurodegenerative Diseases: A Systematic Review and Meta-Analysis. *Sci Rep.* 2024;14(1):9558.
doi: 10.1038/s41598-024-59250-w
58. Becker A, Schmartz GP, Gröger L, *et al.* Effects of Resistant Starch on Symptoms, Fecal Markers, and Gut Microbiota in Parkinson's Disease - The RESISTA-PD Trial. *Genomics Proteomics Bioinformatics.* 2022;20(2):274-287.
doi: 10.1016/j.gpb.2021.08.009
59. Kapoor B, Biswas P, Gulati M, Rani P, Gupta R. Gut Microbiome and Alzheimer's Disease: What We Know and What Remains to Be Explored. *Ageing Res Rev.* 2024;102:102570.
doi: 10.1016/j.arr.2024.102570
60. Ferreira AL, Choi J, Ryou J, *et al.* Gut Microbiome Composition May Be an Indicator of Preclinical Alzheimer's Disease. *Sci Transl Med.* 2023;15(700):eabo2984.
doi: 10.1126/scitranslmed.abo2984
61. Jemimah S, Chabib CMM, Hadjileontiadis L, AlShehhi A. Gut Microbiome Dysbiosis in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. *PLoS One.* 2023;18(5):e0285346.
doi: 10.1371/journal.pone.0285346
62. Zhang T, Gao G, Kwok LY, Sun Z. Gut Microbiome-Targeted Therapies for Alzheimer's Disease. *Gut Microbes.* 2023;15(2):2271613.
doi: 10.1080/19490976.2023.2271613
63. Cuervo-Zanatta D, Garcia-Mena J, Perez-Cruz C. Gut Microbiota Alterations and Cognitive Impairment Are Sexually Dissociated in a Transgenic Mice Model of Alzheimer's Disease. *J Alzheimers Dis.* 2021;82(s1):S195-S214.
doi: 10.3233/JAD-201367
64. Saha S, Singh S, Prasad S, Mittal A, Sharma AK, Chakrabarti S. Gut Microbiota and Alzheimer's Disease: Experimental Evidence and Clinical Reality. *Curr Alzheimer Res.* 2021;18(10):787-801.
doi: 10.2174/1567205018666210907160854
65. Pasupalak JK, Rajput P, Gupta GL. Gut Microbiota and Alzheimer's Disease: Exploring Natural Product Intervention and the Gut-Brain Axis for Therapeutic Strategies. *Eur J Pharmacol.* 2024;984:177022.
doi: 10.1016/j.ejphar.2024.177022
66. Nguyen NM, Cho J, Lee C. Gut Microbiota and Alzheimer's Disease: How to Study and Apply Their Relationship. *Int J Mol Sci.* 2023;24(4):4047.
doi: 10.3390/ijms24044047
67. Li Y, Wang R, Li Q, Wang YJ, Guo J. Gut Microbiota and Alzheimer's Disease: Pathophysiology and Therapeutic Perspectives. *J Alzheimers Dis.* 2021;83(3):963-976.
doi: 10.3233/JAD-210381
68. Kuai XY, Yao XH, Xu LJ, *et al.* Evaluation of Fecal Microbiota Transplantation in Parkinson's Disease Patients with Constipation. *Microb Cell Fact.* 2021;20(1):98.
doi: 10.1186/s12934-021-01589-0
69. Gubert C, Kong G, Renoir T, Hannan AJ. Exercise, Diet and Stress as Modulators of Gut Microbiota: Implications for Neurodegenerative Diseases. *Neurobiol Dis.* 2020;134:104621.
doi: 10.1016/j.nbd.2019.104621
70. Sadowski K, Zajac W, Milanowski Ł, Koziorowski D, Figura M. Exploring Fecal Microbiota Transplantation for Modulating Inflammation in Parkinson's Disease: A Review of Inflammatory Markers and Potential Effects. *Int J Mol Sci.* 2024;25(14):7741.
doi: 10.3390/ijms25147741
71. Ciavarella D, Mastrovincenzo M, D'Onofrio V, *et al.* Saliva Analysis by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS) in Orthodontic Treatment: First Pilot Study. *Prog Orthod.* 2011;12(2):126-131.
doi: 10.1016/j.pio.2011.06.002
72. Ballini A, Cantore S, Signorini L, *et al.* Efficacy of Sea Salt-Based Mouthwash and Xylitol in Improving Oral Hygiene among Adolescent Population: A Pilot Study. *Int J Environ Res Public Health.* 2020;18(1):44.
doi: 10.3390/ijerph18010044
73. Zhang M, Zhai Z, Yang B, *et al.* Exploring the Alteration of Gut Microbiota and Brain Function in Gender-Specific Parkinson's Disease Based on Metagenomic

- Sequencing. *Front Aging Neurosci.* 2023;15:1148546.
doi: 10.3389/fnagi.2023.1148546
74. Cocean AM, Vodnar DC. Exploring the Gut-Brain Axis: Potential Therapeutic Impact of Psychobiotics on Mental Health. *Prog Neuropsychopharmacol Biol Psychiatry.* 2024;134:111073.
doi: 10.1016/j.pnpbp.2024.111073
75. Yang H, Shao Y, Hu Y, *et al.* Fecal Microbiota from Patients with Parkinson's Disease Intensifies Inflammation and Neurodegeneration in A53T Mice. *CNS Neurosci Ther.* 2024;30(8):e70003.
doi: 10.1111/cns.70003
76. Xue LJ, Yang XZ, Tong Q, *et al.* Fecal Microbiota Transplantation Therapy for Parkinson's Disease: A Preliminary Study. *Medicine (Baltimore).* 2020;99(35):e22035.
doi: 10.1097/MD.00000000000022035
77. Açar Y, Ağagündüz D, De Cicco P, Capasso R. Flavonoids: Their Putative Neurologic Roles, Epigenetic Changes, and Gut Microbiota Alterations in Parkinson's Disease. *Biomed Pharmacother.* 2023;168:115788.
doi: 10.1016/j.biopha.2023.115788
78. Vilela C, Araújo B, Soares-Guedes C, *et al.* From the Gut to the Brain: Is Microbiota a New Paradigm in Parkinson's Disease Treatment? *Cells.* 2024;13(9):770.
doi: 10.3390/cells13090770
79. Montalbán-Rodríguez A, Abalo R, López-Gómez L. From the Gut to the Brain: The Role of Enteric Glial Cells and Their Involvement in the Pathogenesis of Parkinson's Disease. *Int J Mol Sci.* 2024;25(2):1294.
doi: 10.3390/ijms25021294
80. Leta V, Klingelhofer L, Longardner K, *et al.* Gastrointestinal Barriers to Levodopa Transport and Absorption in Parkinson's Disease. *Eur J Neurol.* 2023;30(5):1465-1480.
doi: 10.1111/ene.15734
81. Pellegrini C, Travagli RA. Gastrointestinal Dysmotility in Rodent Models of Parkinson's Disease. *Am J Physiol Gastrointest Liver Physiol.* 2024;326(4):G345-G359.
doi: 10.1152/ajpgi.00225.2023
82. Jones JD, Rahmani E, Garcia E, Jacobs JP. Gastrointestinal Symptoms Are Predictive of Trajectories of Cognitive Functioning in de Novo Parkinson's Disease. *Parkinsonism Relat Disord.* 2020;72:7-12.
doi: 10.1016/j.parkreldis.2020.01.009
83. Li Z, Liang H, Hu Y, *et al.* Gut Bacterial Profiles in Parkinson's Disease: A Systematic Review. *CNS Neurosci Ther.* 2023;29(1):140-157.
doi: 10.1111/cns.13990
84. Naito Y. Gut Frailty: Its Concept and Pathogenesis. *Digestion.* 2024;105(1):49-57.
doi: 10.1159/000534733
85. Salim S, Ahmad F, Banu A, Mohammad F. Gut Microbiome and Parkinson's Disease: Perspective on Pathogenesis and Treatment. *J Adv Res.* 2023;50:83-105.
doi: 10.1016/j.jare.2022.10.013
86. Huang B, Chau SWH, Liu Y, *et al.* Gut Microbiome Dysbiosis across Early Parkinson's Disease, REM Sleep Behavior Disorder and Their First-Degree Relatives. *Nat Commun.* 2023;14(1):2501.
doi: 10.1038/s41467-023-38248-4
87. Kalyanaraman B, Cheng G, Hardy M. Gut Microbiome, Short-Chain Fatty Acids, Alpha-Synuclein, Neuroinflammation, and ROS/RNS: Relevance to Parkinson's Disease and Therapeutic Implications. *Redox Biol.* 2024;71:103092.
doi: 10.1016/j.redox.2024.103092
88. Kustrimovic N, Balkhi S, Bilato G, Mortara L. Gut Microbiota and Immune System Dynamics in Parkinson's and Alzheimer's Diseases. *Int J Mol Sci.* 2024;25(22):12164.
doi: 10.3390/ijms252212164
89. Yan Y, Ren S, Duan Y, *et al.* Gut Microbiota and Metabolites of α -Synuclein Transgenic Monkey Models with Early Stage of Parkinson's Disease. *NPJ Biofilms Microbiomes.* 2021;7(1):69.
doi: 10.1038/s41522-021-00242-3
90. Wang L, Cui Y, Han B, *et al.* Gut Microbiota and Parkinson's Disease. *Chin Med J (Engl).* 2025;138(3):289-297.
doi: 10.1097/CM9.0000000000003318
91. Kang Y, Kang X, Zhang H, Liu Q, Yang H, Fan W. Gut Microbiota and Parkinson's Disease: Implications for Faecal Microbiota Transplantation Therapy. *ASN Neuro.* 2021;13:17590914211016217.
doi: 10.1177/17590914211016217
92. Liu J, Xu F, Nie Z, Shao L. Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease. *Front Cell Infect Microbiol.* 2020;10:570658.
doi: 10.3389/fcimb.2020.570658
93. Heravi FS, Naseri K, Hu H. Gut Microbiota Composition in Patients with Neurodegenerative Disorders (Parkinson's and Alzheimer's) and Healthy Controls: A Systematic Review. *Nutrients.* 2023;15(20):4365.
doi: 10.3390/nu15204365
94. Nohesara S, Abdolmaleky HM, Thiagalingam S, Zhou JR. Gut Microbiota Defined Epigenomes of Alzheimer's and Parkinson's Diseases Reveal Novel Targets for Therapy. *Epigenomics.* 2024;16(1):57-77.
doi: 10.2217/epi-2023-0342

95. Fang X, Liu S, Muhammad B, *et al.* Gut Microbiota Dysbiosis Contributes to α -Synuclein-Related Pathology Associated with C/EBP β /AEP Signaling Activation in a Mouse Model of Parkinson's Disease. *Neural Regen Res.* 2024;19(9):2081-2088.
doi: 10.4103/1673-5374.391191
96. Wang JY, Xie R, Feng Y, *et al.* Gut Microbiota Helps Identify Clinical Subtypes of Parkinson's Disease. *Mil Med Res.* 2024;11(1):42.
doi: 10.1186/s40779-024-00545-4
97. Mou Y, Du Y, Zhou L, *et al.* Gut Microbiota Interact With the Brain Through Systemic Chronic Inflammation: Implications on Neuroinflammation, Neurodegeneration, and Aging. *Front Immunol.* 2022;13:796288.
doi: 10.3389/fimmu.2022.796288
98. Nakahara K, Nakane S, Ishii K, Ikeda T, Ando Y. Gut Microbiota of Parkinson's Disease in an Appendectomy Cohort: A Preliminary Study. *Sci Rep.* 2023;13(1):2210.
doi: 10.1038/s41598-023-29219-2
99. Fernández-Calvet A, Matilla-Cuenca L, Izco M, *et al.* Gut Microbiota Produces Biofilm-Associated Amyloids with Potential for Neurodegeneration. *Nat Commun.* 2024;15(1):4150.
doi: 10.1038/s41467-024-48309-x
100. Cui C, Song H, Han Y, *et al.* Gut Microbiota-Associated Taurine Metabolism Dysregulation in a Mouse Model of Parkinson's Disease. *mSphere.* 2023;8(6):e0043123.
doi: 10.1128/msphere.00431-23
101. Hou YF, Shan C, Zhuang SY, *et al.* Gut Microbiota-Derived Propionate Mediates the Neuroprotective Effect of Osteocalcin in a Mouse Model of Parkinson's Disease. *Microbiome.* 2021;9(1):34.
doi: 10.1186/s40168-020-00988-6
102. Ji D, Chen WZ, Zhang L, Zhang ZH, Chen LJ. Gut Microbiota, Circulating Cytokines and Dementia: A Mendelian Randomization Study. *J Neuroinflammation.* 2024;21(1):2.
doi: 10.1186/s12974-023-02999-0
103. Zhu M, Liu X, Ye Y, *et al.* Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease. *Front Immunol.* 2022;13:937555.
doi: 10.3389/fimmu.2022.937555
104. Riegelman E, Xue KS, Wang JS, Tang L. Gut-Brain Axis in Focus: Polyphenols, Microbiota, and Their Influence on α -Synuclein in Parkinson's Disease. *Nutrients.* 2024;16(13):2041.
doi: 10.3390/nu16132041
105. Munoz-Pinto MF, Candeias E, Melo-Marques I, *et al.* Gut-First Parkinson's Disease Is Encoded by Gut Dysbiome. *Mol Neurodegener.* 2024;19(1):78.
doi: 10.1186/s13024-024-00766-0
106. Claudino Dos Santos JC, Oliveira LE, Noleto FM, *et al.* Gut-Microbiome-Brain Axis: The Crosstalk between the Vagus Nerve, Alpha-Synuclein and the Brain in Parkinson's Disease. *Neural Regen Res.* 2023;18(12):2611-2614.
doi: 10.4103/1673-5374.373673
107. Lin CH, Lai HC, Wu MS. Gut-Oriented Disease Modifying Therapy for Parkinson's Disease. *J Formos Med Assoc.* 2023;122(1):9-18.
doi: 10.1016/j.jfma.2022.09.010
108. Dipalma G, Marinelli G, Ferrante L, *et al.* Modulating the Gut Microbiota to Target Neuroinflammation, Cognition and Mood: A Systematic Review of Human Studies with Relevance to Fibromyalgia. *Nutrients.* 2025;17(14):2261.
doi: 10.3390/nu17142261. PMID: 40732886
109. Contaldo M, Fusco A, Stiuso P, *et al.* Oral Microbiota and Salivary Levels of Oral Pathogens in Gastro-Intestinal Diseases: Current Knowledge and Exploratory Study. *Microorganisms.* 2021;9(5):1064.
doi: 10.3390/microorganisms9051064. PMID: 34069179
110. Isacco CG, Ballini A, De Vito D, *et al.* Rebalancing the Oral Microbiota as an Efficient Tool in Endocrine, Metabolic and Immune Disorders. *Endocr Metab Immune Disord Drug Targets.* 2021;21(5):777-784.
doi: 10.2174/1871530320666200729142504. PMID: 32727337
111. Ballini A, Dipalma G, Isacco CG, *et al.* Oral Microbiota and Immune System Crosstalk: A Translational Research. *Biology (Basel).* 2020;9(6):131.
doi: 10.3390/biology9060131. PMID: 32560235
112. Signorini L, Ballini A, Arrigoni R, *et al.* Evaluation of a Nutraceutical Product with Probiotics, Vitamin D, Plus Banaba Leaf Extracts (*Lagerstroemia speciosa*) in Glycemic Control. *Endocr Metab Immune Disord Drug Targets.* 2021;21(7):1356-1365.
doi: 10.2174/1871530320666201109115415. PMID: 33167849
113. Santacroce L, Inchingolo F, Topi S, *et al.* Potential beneficial role of probiotics on the outcome of COVID-19 patients: An evolving perspective. *Diabetes Metab Syndr.* 2021;15(1):295-301.
doi: 10.1016/j.dsx.2020.12.040. PMID: 33484986
114. Gasparro R, Sammartino G, Mariniello M, di Lauro AE, Spagnuolo G, Marenzi G. Treatment of Periodontal Pockets at the Distal Aspect of Mandibular Second Molar after Surgical Removal of Impacted Third Molar and Application of L-PRF: A Split-Mouth Randomized Clinical

- Trial. *Quintessence Int.* 2020;51:204-211.
doi: 10.3290/j.qi.a43947
115. Adamo D, Gasparro R, Marenzi G, *et al.* Amyloidoma of the Tongue: Case Report, Surgical Management, and Review of the Literature. *J Oral Maxillofac Surg.* 2020;78(9):1572-1582.
doi: 10.1016/j.joms.2020.04.022
116. Shen L. Gut, Oral and Nasal Microbiota and Parkinson's Disease. *Microb Cell Fact.* 2020;19(1):50.
doi: 10.1186/s12934-020-01313-4
117. Baj J, Forma A, Flieger W, *et al.* Helicobacter Pylori Infection and Extragastric Diseases-A Focus on the Central Nervous System. *Cells.* 2021;10(9):2191.
doi: 10.3390/cells10092191
118. Zhang F, Pan L, Lian C, *et al.* ICAM-1 May Promote the Loss of Dopaminergic Neurons by Regulating Inflammation in MPTP-Induced Parkinson's Disease Mouse Models. *Brain Res Bull.* 2024;214:110989.
doi: 10.1016/j.brainresbull.2024.110989
119. Hamamah S, Hajnal A, Covasa M. Impact of Nutrition, Microbiota Transplant and Weight Loss Surgery on Dopaminergic Alterations in Parkinson's Disease and Obesity. *Int J Mol Sci.* 2022;23(14):7503.
doi: 10.3390/ijms23147503
120. Smeyne RJ, Noyce AJ, Byrne M, Savica R, Marras C. Infection and Risk of Parkinson's Disease. *J Parkinsons Dis.* 2021;11(1):31-43.
doi: 10.3233/JPD-202279
121. Das TK, Ganesh BP. Interlink between the Gut Microbiota and Inflammation in the Context of Oxidative Stress in Alzheimer's Disease Progression. *Gut Microbes.* 2023;15(1):2206504.
doi: 10.1080/19490976.2023.2206504
122. Goldoni R, Dolci C, Boccalari E, *et al.* Salivary biomarkers of neurodegenerative and demyelinating diseases and biosensors for their detection. *Ageing Res Rev.* 2022;76:101587.
doi: 10.1016/j.arr.2022.101587. PMID: 35151849
123. Szablewski L. Human Gut Microbiota in Health and Alzheimer's Disease. *J Alzheimers Dis.* 2018;62(2):549-560.
doi: 10.3233/JAD-170908
124. Inchingolo AM, Gargiulo Isacco C, Inchingolo AD, *et al.* The human microbiota key role in the bone metabolism activity. *Eur Rev Med Pharmacol Sci.* 2023;27(6):2659-2670.
doi: 10.26355/eurrev_202303_31803. PMID: 37013784
125. Inchingolo AD, Malcangi G, Inchingolo AM, *et al.* Benefits and Implications of Resveratrol Supplementation on Microbiota Modulations: A Systematic Review of the Literature. *Int J Mol Sci.* 2022;23(7):4027.
doi: 10.3390/ijms23074027. PMID: 35409389
126. Verhaar BJH, Hendriksen HMA, de Leeuw FA, *et al.* Gut Microbiota Composition Is Related to AD Pathology. *Front Immunol.* 2021;12:794519.
doi: 10.3389/fimmu.2021.794519
127. Nohesara S, Abdolmaleky HM, Thiagalingam S, Zhou JR. Gut Microbiota Defined Epigenomes of Alzheimer's and Parkinson's Diseases Reveal Novel Targets for Therapy. *Epigenomics.* 2024;16(1):57-77.
doi: 10.2217/epi-2023-0342
128. Manfredi JN, Gupta SK, Vyavahare S, *et al.* Gut Microbiota Dysbiosis in Alzheimer's Disease (AD): Insights from Human Clinical Studies and the Mouse AD Models. *Physiol Behav.* 2025;290:114778.
doi: 10.1016/j.physbeh.2024.114778
129. Zhang B, Chen T, Cao M, *et al.* Gut Microbiota Dysbiosis Induced by Decreasing Endogenous Melatonin Mediates the Pathogenesis of Alzheimer's Disease and Obesity. *Front Immunol.* 2022;13:900132.
doi: 10.3389/fimmu.2022.900132
130. Luca M, Di Mauro M, Di Mauro M, Luca A. Gut Microbiota in Alzheimer's Disease, Depression, and Type 2 Diabetes Mellitus: The Role of Oxidative Stress. *Oxid Med Cell Longev.* 2019;2019:4730539.
doi: 10.1155/2019/4730539
131. Hung CC, Chang CC, Huang CW, Nouchi R, Cheng CH. Gut Microbiota in Patients with Alzheimer's Disease Spectrum: A Systematic Review and Meta-Analysis. *Aging.* 2022;14(1):477-496.
doi: 10.18632/aging.203826
132. Mou Y, Du Y, Zhou L, *et al.* Gut Microbiota Interact With the Brain Through Systemic Chronic Inflammation: Implications on Neuroinflammation, Neurodegeneration, and Aging. *Front Immunol.* 2022;13:796288.
doi: 10.3389/fimmu.2022.796288
133. Zhuang ZQ, Shen LL, Li WW, *et al.* Gut Microbiota Is Altered in Patients with Alzheimer's Disease. *J Alzheimers Dis.* 2018;63(4):1337-1346.
doi: 10.3233/JAD-180176
134. Junyi L, Yueyang W, Bin L, *et al.* Gut Microbiota Mediates Neuroinflammation in Alzheimer's Disease: Unraveling Key Factors and Mechanistic Insights. *Mol Neurobiol.* 2025;62(3):3746-3763.
doi: 10.1007/s12035-024-04513-w
135. Bonfili L, Cuccioloni M, Gong C, *et al.* Gut Microbiota Modulation in Alzheimer's Disease: Focus on Lipid Metabolism. *Clin Nutr.* 2022;41(3):698-708.

- doi: 10.1016/j.clnu.2022.01.025
136. Ağagündüz D, Kocaadam-Bozkurt B, Bozkurt O, *et al.* Microbiota Alteration and Modulation in Alzheimer's Disease by Gerobiotics: The Gut-Health Axis for a Good Mind. *Biomed Pharmacother.* 2022;153:113430.
doi: 10.1016/j.biopha.2022.113430
 137. Inchingolo F, Inchingolo AD, Palumbo I, *et al.* The Impact of Cesarean Section Delivery on Intestinal Microbiota: Mechanisms, Consequences, and Perspectives-A Systematic Review. *Int J Mol Sci.* 2024;25(2):1055.
doi: 10.3390/ijms25021055. PMID: 38256127
 138. Zorina SA, Jurja S, Mehedinti M, *et al.* Infectious Microorganisms Seen as Etiologic Agents in Parkinson's Disease. *Life.* 2023;13(3):805.
doi: 10.3390/life13030805
 139. Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and Immune Dysfunction in Parkinson Disease. *Nat Rev Immunol.* 2022;22(11):657-673.
doi: 10.1038/s41577-022-00684-6
 140. Fan T, Li X, Zhang X, *et al.* Influence of Aerobic Exercise Training on Mice Gut Microbiota in Parkinson's Disease. *Turk J Biol.* 2022;46(4):288-297.
doi: 10.55730/1300-0152.2617
 141. Hertel J, Harms AC, Heinken A, *et al.* Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson's Disease. *Cell Rep.* 2019;29(7):1767-1777.e8.
doi: 10.1016/j.celrep.2019.10.035
 142. Shandilya S, Kumar S, Kumar Jha N, Kumar Kesari K, Ruokolainen J. Interplay of Gut Microbiota and Oxidative Stress: Perspective on Neurodegeneration and Neuroprotection. *J Adv Res.* 2022;38:223-244.
doi: 10.1016/j.jare.2021.09.005
 143. Liu J, Chen Q, Su R. Interplay of Human Gastrointestinal Microbiota Metabolites: Short-Chain Fatty Acids and Their Correlation with Parkinson's Disease. *Medicine (Baltimore).* 2024;103(17):e37960.
doi: 10.1097/MD.00000000000037960
 144. Hegelmaier T, Lebbling M, Duscha A, *et al.* Interventional Influence of the Intestinal Microbiome Through Dietary Intervention and Bowel Cleansing Might Improve Motor Symptoms in Parkinson's Disease. *Cells.* 2020;9(2):376.
doi: 10.3390/cells9020376
 145. Jiang T, Wang Y, Fan W, *et al.* Intestinal Microbiota Distribution and Changes in Different Stages of Parkinson's Disease: A Meta-Analysis, Bioinformatics Analysis and in Vivo Simulation. *Biosci Trends.* 2025;19(1):87-101.
doi: 10.5582/bst.2024.01352
 146. Tao Y, Leng SX, Zhang H. Ketogenic Diet: An Effective Treatment Approach for Neurodegenerative Diseases. *Curr Neuroparmacol.* 2022;20(12):2303-2319.
doi: 10.2174/1570159X20666220830102628
 147. Chu C, Yu L, Li Y, *et al.* Lactobacillus Plantarum CCFM405 against Rotenone-Induced Parkinson's Disease Mice via Regulating Gut Microbiota and Branched-Chain Amino Acids Biosynthesis. *Nutrients.* 2023;15(7):1737.
doi: 10.3390/nu15071737
 148. Page MJ, McKenzie JE, Bossuyt PM, *et al.* The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. *BMJ.* 2021;372:n71.
doi: 10.1136/bmj.n71
 149. Inchingolo AM, Malcangi G, Piras F, *et al.* Precision Medicine on the Effects of Microbiota on Head-Neck Diseases and Biomarkers Diagnosis. *J Pers Med.* 2023;13(6):933.
doi: 10.3390/jpm13060933. PMID: 37373922
 150. Corriero A, Gadaleta RM, Puntillo F, Inchingolo F, Moschetta A, Brienza N. The central role of the gut in intensive care. *Crit Care.* 2022;26(1):379.
doi: 10.1186/s13054-022-04259-8. PMID: 36476497
 151. Inchingolo AD, Cazzolla AP, Di Cosola M, *et al.* The integumentary system and its microbiota between health and disease. *J Biol Regul Homeost Agents.* 2021;35(2 Suppl 1):303-321.
doi: 10.23812/21-2suppl1-30.
 152. Corriero A, Giglio M, Soloperto R, Inchingolo F, Varrassi G, Puntillo F. Microbial Symphony: Exploring the Role of the Gut in Osteoarthritis-Related Pain. A Narrative Review. *Pain Ther.* 2024;13(3):409-433.
doi: 10.1007/s40122-024-00602-9. PMID: 38678155
 153. Arıkan M, Demir TK, Yıldız Z, *et al.* Metaproteogenomic Analysis of Saliva Samples from Parkinson's Disease Patients with Cognitive Impairment. *NPJ Biofilms Microbiomes.* 2023;9(1):86.
doi: 10.1038/s41522-023-00452-x
 154. Borzabadi S, Oryan S, Eidi A, *et al.* The Effects of Probiotic Supplementation on Gene Expression Related to Inflammation, Insulin and Lipid in Patients with Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. *Arch Iran Med.* 2018;21:289-295.
 155. Vendrik KE, Chernova VO, Kuijper EJ, Terveer EM, van Hilten JJ, Contarino MF; FMT4PD study group. Safety and Feasibility of Faecal Microbiota Transplantation for Patients with Parkinson's Disease: A Protocol for a Self-Controlled Interventional Donor-FMT Pilot Study. *BMJ Open.* 2023;13(10):e071766.
doi: 10.1136/bmjopen-2023-071766

156. Cheng Y, Tan G, Zhu Q, *et al.* Efficacy of Fecal Microbiota Transplantation in Patients with Parkinson's Disease: Clinical Trial Results from a Randomized, Placebo-Controlled Design. *Gut Microbes.* 2023;15(2):2284247.
doi: 10.1080/19490976.2023.2284247
157. Barichella M, Severgnini M, Cilia R, *et al.* Unraveling Gut Microbiota in Parkinson's Disease and Atypical Parkinsonism. *Mov Disord.* 2019;34(3):396-405.
doi: 10.1002/mds.27581
158. Rusch C, Beke M, Nieves C, *et al.* Promotion of a Mediterranean Diet alters Constipation Symptoms and Fecal Calprotectin in People with Parkinson's Disease: A Randomized Controlled Trial. *Nutrients.* 2024;16(17):2946.
doi: 10.3390/nu16172946
159. Du Y, Li Y, Xu X, *et al.* Probiotics for Constipation and Gut Microbiota in Parkinson's Disease. *Parkinsonism Relat Disord.* 2022;103:92-97.
doi: 10.1016/j.parkreldis.2022.08.022
160. Seelarbokus BA, Menozzi E, Schapira AHV, Kalea AZ, Macnaughtan J. Mediterranean Diet Adherence, Gut Microbiota and Parkinson's Disease: A Systematic Review. *Nutrients.* 2024;16(14):2181.
doi: 10.3390/nu16142181
161. Solch RJ, Aigbogun JO, Voyiadjis AG, *et al.* Mediterranean Diet Adherence, Gut Microbiota, and Alzheimer's or Parkinson's Disease Risk: A Systematic Review. *J Neurol Sci.* 2022;434:120166.
doi: 10.1016/j.jns.2022.120166
162. Bisaglia M. Mediterranean Diet and Parkinson's Disease. *Int J Mol Sci.* 2022;24(1):42.
doi: 10.3390/ijms24010042
163. Zhou S, Li B, Deng Y, *et al.* Meta-Analysis of the Relations between Gut Microbiota and Pathogens and Parkinson's Disease. *Adv Clin Exp Med.* 2023;32(6):613-621.
doi: 10.17219/acem/157193
164. Hamilton AM, Krout IN, White AC, Sampson TR. Microbiome-Based Therapeutics for Parkinson's Disease. *Neurotherapeutics.* 2024;21(6):e00462.
doi: 10.1016/j.neurot.2024.e00462
165. Alam M, Abbas K, Mustafa M, Usmani N, Habib S. Microbiome-Based Therapies for Parkinson's Disease. *Front Nutr.* 2024;11:1496616.
doi: 10.3389/fnut.2024.1496616
166. Lin CH, Chen CC, Chiang HL, *et al.* Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease. *J Neuroinflammation.* 2019;16(1):129.
doi: 10.1186/s12974-019-1528-y
167. Lin SH, Lin RJ, Chu CL, Chen YL, Fu SC. Associations Between Gut Microbiota Composition and Impulse Control Disorders in Parkinson's Disease. *Int J Mol Sci.* 2025;26(13):6146.
doi: 10.3390/ijms26136146
168. Pietrucci D, Teofani A, Unida V, *et al.* Can Gut Microbiota Be a Good Predictor for Parkinson's Disease? A Machine Learning Approach. *Brain Sci.* 2020;10(4):242.
doi: 10.3390/brainsci10040242
169. Lee HG, Kwon S, Yeom M, Bae SY, Park HJ. Changes in Gut Microbiome Following Acupuncture and Moxibustion in Patients With Parkinson Disease: Protocol for a Single-Group, Prospective, Observational Study. *JMIR Res Protoc.* 2025;14:e76551.
doi: 10.2196/76551
170. Mao L, Zhang Y, Tian J, *et al.* Cross-Sectional Study on the Gut Microbiome of Parkinson's Disease Patients in Central China. *Front Microbiol.* 2021;12:728479.
doi: 10.3389/fmicb.2021.728479
171. Kwon D, Zhang K, Paul KC, Folle AD, *et al.* Diet and the gut microbiome in patients with Parkinson's disease. *NPJ Parkinsons Dis.* 2024;10(1):89.
doi: 10.1038/s41531-024-00681-7
172. Zapala B, Stefura T, Wójcik-Pędzwiatr M, *et al.* Differences in the Composition of Gut Microbiota between Patients with Parkinson's Disease and Healthy Controls: A Cohort Study. *J Clin Med.* 2021;10(23):5698.
doi: 10.3390/jcm10235698
173. Costa HN, Esteves AR, Empadinhas N, Cardoso SM. Parkinson's Disease: A Multisystem Disorder. *Neurosci Bull.* 2023;39(1):113-124.
doi: 10.1007/s12264-022-00934-6
174. Vascellari S, Manzin A. Parkinson's Disease: A Prionopathy? *Int J Mol Sci.* 2021;22(15):8022.
doi: 10.3390/ijms22158022
175. Bhattarai Y, Kashyap PC. Parkinson's Disease: Are Gut Microbes Involved? *Am J Physiol Gastrointest Liver Physiol.* 2020;319(5):G529-G540.
doi: 10.1152/ajpgi.00058.2020
176. Omotosho AO, Tajudeen YA, Oladipo HJ, *et al.* Parkinson's Disease: Are Gut Microbes Involved? *Brain Behav.* 2023;13(8):e3130.
doi: 10.1002/brb3.3130
177. Zhang N, Guo P, Zhao Y, *et al.* Pharmacological Mechanisms of Puerarin in the Treatment of Parkinson's Disease: An Overview. *Biomed Pharmacother.* 2024;177:117101.
doi: 10.1016/j.biopha.2024.117101

178. Zhang Y, Mo C, Ai P, He X, Xiao Q, Yang X. Pharmacomicrobiomics: A New Field Contributing to Optimizing Drug Therapy in Parkinson's Disease. *Gut Microbes*. 2025;17(1):2454937.
doi: 10.1080/19490976.2025.2454937
179. Goya ME, Xue F, Sampedro-Torres-Quevedo C, et al. Probiotic *Bacillus subtilis* Protects against α -Synuclein Aggregation in *C. elegans*. *Cell Rep*. 2020;30(2):367-380.e7.
doi: 10.1016/j.celrep.2019.12.078
180. Oroojzadeh P, Bostanabad SY, Lotfi H. Psychobiotics: The Influence of Gut Microbiota on the Gut-Brain Axis in Neurological Disorders. *J Mol Neurosci*. 2022;72(9):1952-1964.
doi: 10.1007/s12031-022-02053-3
181. Chen Y, Xu J, Chen Y. Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders. *Nutrients*. 2021;13(6):2099.
doi: 10.3390/nu13062099
182. Yuan XY, Chen YS, Liu Z. Relationship among Parkinson's Disease, Constipation, Microbes, and Microbiological Therapy. *World J Gastroenterol*. 2024;30(3):225-237.
doi: 10.3748/wjg.v30.i3.225
183. Aho VTE, Houser MC, Pereira PAB, et al. Relationships of Gut Microbiota, Short-Chain Fatty Acids, Inflammation, and the Gut Barrier in Parkinson's Disease. *Mol Neurodegener*. 2021;16(1):6.
doi: 10.1186/s13024-021-00427-6
184. Zhang W, Ye Y, Song J, et al. Research Progress of Microbiota-Gut-Brain Axis in Parkinson's Disease. *J Integr Neurosci*. 2023;22(6):157.
doi: 10.31083/j.jin2206157
185. Yuan C, He Y, Xie K, Feng L, Gao S, Cai L. Review of Microbiota Gut Brain Axis and Innate Immunity in Inflammatory and Infective Diseases. *Front Cell Infect Microbiol*. 2023;13:1282431.
doi: 10.3389/fcimb.2023.1282431
186. Huang Y, Liao J, Liu X, Zhong Y, Cai X, Long L. Review: The Role of Intestinal Dysbiosis in Parkinson's Disease. *Front Cell Infect Microbiol*. 2021;11:615075.
doi: 10.3389/fcimb.2021.615075
187. Hong CT, Chan L, Chen KY, et al. Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson's Disease: Preclinical and Clinical Studies. *Cells*. 2022;11(21):3468.
doi: 10.3390/cells11213468
188. Mirzaei R, Bouzari B, Hosseini-Fard SR, et al. Role of Microbiota-Derived Short-Chain Fatty Acids in Nervous System Disorders. *Biomed Pharmacother*. 2021;139:111661.
doi: 10.1016/j.biopha.2021.111661
189. Ioghen OC, Ceafalan LC, Popescu BO. SH-SY5Y Cell Line In Vitro Models for Parkinson Disease Research-Old Practice for New Trends. *J Integr Neurosci*. 2023;22(1):20.
doi: 10.31083/j.jin2201020
190. Nguyen TT, Baumann P, Tüscher O, Schick S, Endres K. The Aging Enteric Nervous System. *Int J Mol Sci*. 2023;24(11):9471.
doi: 10.3390/ijms24119471
191. Carloni S, Rescigno M. The Gut-Brain Vascular Axis in Neuroinflammation. *Semin Immunol*. 2023;69:101802.
doi: 10.1016/j.smim.2023.101802
192. Manos J. The Human Microbiome in Disease and Pathology. *APMIS*. 2022;130(12):690-705.
doi: 10.1111/apm.13225
193. Varesi A, Campagnoli LIM, Fahmideh F, et al. The Interplay between Gut Microbiota and Parkinson's Disease: Implications on Diagnosis and Treatment. *Int J Mol Sci*. 2022;23(20):12289.
doi: 10.3390/ijms232012289
194. Zheng Y, Bonfili L, Wei T, Eleuteri AM. Understanding the Gut-Brain Axis and Its Therapeutic Implications for Neurodegenerative Disorders. *Nutrients*. 2023;15(21):4631.
doi: 10.3390/nu15214631
195. Neufeld PM, Nettersheim RA, Matschke V, Vorgerd M, Stahlke S, Theiss C. Unraveling the Gut-Brain Axis: The Impact of Steroid Hormones and Nutrition on Parkinson's Disease. *Neural Regen Res*. 2024;19(10):2219-2228.
doi: 10.4103/1673-5374.391304
196. Sun X, Xue L, Wang Z, Xie A. Update to the Treatment of Parkinson's Disease Based on the Gut-Brain Axis Mechanism. *Front Neurosci*. 2022;16:878239.
doi: 10.3389/fnins.2022.878239
197. Wojciechowska O, Kujawska M. Urolithin A in Health and Diseases: Prospects for Parkinson's Disease Management. *Antioxidants (Basel)*. 2023;12(7):1479.
doi: 10.3390/antiox12071479
198. Reiner O, Sapir T, Parichha A. Using Multi-Organ Culture Systems to Study Parkinson's Disease. *Mol Psychiatry*. 2021;26(3):725-735.
doi: 10.1038/s41380-020-00936-8
199. Bonnechère B, Amin N, van Duijn C. What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review. *Int J Mol Sci*. 2022;23(22):13665.
doi: 10.3390/ijms232213665
200. Wronka D, Karlik A, Misiorek JO, Przybyl L. What the Gut Tells the Brain-Is There a Link between Microbiota and

- Huntington's Disease? *Int J Mol Sci.* 2023;24(5):4477.
doi: 10.3390/ijms24054477
201. Ré DB, Rideout HJ. Why the Gut Microbiome Must Be Considered When Evaluating the Impact of Pesticides on Parkinson's Disease Risk. *J Parkinsons Dis.* 2023;13(7):1077-1078.
doi: 10.3233/JPD-239004
202. Signorini L, De Leonardi F, Santacroce L, *et al.* Probiotics may modulate the impact of aging on adults. *J Biol Regul Homeost Agents.* 2020;34(4):1601-1606.
doi: 10.23812/20-393-L. PMID: 32909421
203. Inchingolo AM, Patano A, Piras F, *et al.* Interconnection between Microbiota-Gut-Brain Axis and Autism Spectrum Disorder Comparing Therapeutic Options: A Scoping Review. *Microorganisms.* 2023;11(6):1477.
doi: 10.3390/microorganisms11061477. PMID: 37374979
204. Chen Y, Xu J, Chen Y. Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders. *Nutrients.* 2021;13(6):2099.
doi: 10.3390/nu13062099
205. Dissanayaka DMS, Jayasena V, Rainey-Smith SR, Martins RN, Fernando WMADB. The Role of Diet and Gut Microbiota in Alzheimer's Disease. *Nutrients.* 2024;16(3):412.
doi: 10.3390/nu16030412